Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Want to put some lead in your pencil? Try nitinol instead.
The wonder metal—a nickel-titanium alloy with heat-activated shape memory—has proved essential for Wisconsin and Illinois researchers building what British tabloids are calling a “bionic penis.” Read more
Terumo Corp. said today it inked a Japanese distribution deal with Xenex to distribute its Xenex LightStrike Germ-Zapping Robots in the region.
The LightStrike device is designed to use pulsed xenon ultraviolet room disinfection technology to remove pathogens such as C. diff, staphylococcus aureus and carbapenem-resistent Enterobacteriaceae, Terumo said. The Xenex LightStrike device has also been shown to be effective against Ebola and Anthrax, the company added. Read more
Taris Biomedical said today that it closed initial enrollment in its phase Ib clinical trial following positive results. The study is evaluating the safety and efficacy of its drug-device combination product that releases gemcitabine continuously into the bladder for 7 days in patients with muscle invasive bladder cancer.
Although the study was slated to enroll up to 20 patients, the Lexington, Mass.-based company decided to close enrollment after observing promising preliminary results in 8 out of 10 patients. Early data showed that the system was well tolerated over 2 week-long treatment periods, with a 14-day resting period in between treatments. Researchers observed tumor responses such as complete tumor ablation and substantial shrinkage in 8 patients. Read more
Pfizer has agreed to take a $100 million hit on its previously $1 billion sale of its Hospira infusion pump business to ICU Medical, bringing in approximately $900 million.
The revised deal calls for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional possible $225 million in cash based on performance milestones through the end of 2019. Read more
Globus Medical said today that it won CE Mark approval in the European Union for the Excelsius GPS robotic guidance device it acquired 3 years ago.
Audubon, Pa.-based Globus said the Excelsius GPS system is for use in both minimally invasive and open procedures for orthopedics and neurosurgery, including procedures for the spine, long bones and cranium. It’s designed to integrate with Globus Medical implants and instruments, with compatibility with pre- and intra-operative CT and fluoroscopic imaging. Read more